GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes

被引：0
|
作者：
Alsakarneh, Saqr [1 ]
Madi, Mahmoud [2 ]
Abuassi, Mohammad [3 ]
Jaber, Fouad [1 ]
Khadra, Majd [4 ]
Numan, Laith [2 ]
Syn, Wing-Kin [2 ]
机构：
[1] Univ Missouri, Kansas City Sch Med, Kansas City, MO USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Univ Cent Florida, HCA Healthcare GME, Gainesville, FL USA
[4] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001036968.88400.f3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1900
引用
收藏
页码：S1364 / S1364
页数：1
相关论文
共 50 条
  • [21] What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?
    Escalada San Martin, Francisco Javier
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (08) : 587 - 589
  • [22] Hepatocellular carcinoma and non-alcoholic fatty liver disease
    Golabi, Pegah
    Rhea, Logan
    Henry, Linda
    Younossi, Zobair M.
    HEPATOLOGY INTERNATIONAL, 2019, 13 (06) : 688 - 694
  • [23] Hepatocellular carcinoma and non-alcoholic fatty liver disease
    Pegah Golabi
    Logan Rhea
    Linda Henry
    Zobair M. Younossi
    Hepatology International, 2019, 13 : 688 - 694
  • [24] THE CHARACTERISTICS AND RISK FACTORS OF HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS.
    Tobari, Maki
    Hashimoto, Etsuko
    Taniai, Makiko
    Sagawa, Takaomi
    Kodama, Kazuhisa
    Kogiso, Tomomi
    Nishino, Takayoshi
    Tokushige, Katsutoshi
    HEPATOLOGY, 2019, 70 : 1344A - 1344A
  • [25] EFFECT OF ANTI-DIABETES MEDICATIONS ON THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Kramer, Jennifer R.
    Natarajan, Yamini
    Dai, Jianliang
    Yu, Xian
    Li, Liang
    Richardson, Peter
    El-Serag, Hashem B.
    Kanwal, Fasiha
    GASTROENTEROLOGY, 2020, 158 (06) : S1271 - S1272
  • [26] Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
    El Dahan, Karim Seif
    Daher, Darine
    Singal, Amit G.
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S207 - S219
  • [27] Non-alcoholic fatty liver disease and type 1 diabetes
    Moreno-Ruiz, I.
    Martin-Timon, I.
    Modamio-Molina, J.
    Bacete-Cebrian, S.
    Zubillaga-Gomez, M.
    Zeng, L.
    Meizoso-Pita, O.
    Trivino-Yannuzzi, V.
    Huguet-Moreno, I.
    Llavero-Valero, M.
    Lara-Moreno, C.
    Sevillano-Collantes, C.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S408 - S408
  • [28] GASTROPARESIS RISK IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED GLP-1 RECEPTOR AGONISTS
    Qapaja, Thabet
    Hamid, Osama
    Abu-Rumaileh, Mohammed
    Kaya, Gizem
    Saleh, Sherif
    Garg, Samita
    GASTROENTEROLOGY, 2024, 166 (05) : S204 - S204
  • [29] Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes
    Lakhan, Manpreet
    Denning, Michael
    Varughese, George I.
    Varadhan, Lakshminara-Yanan
    DIABETES, 2011, 60 : A684 - A684
  • [30] Hepatocellular Carcinoma Occurence in Non-alcoholic Fatty Liver Disease Without Established Cirrhosis
    Lo, S. T.
    Gane, E.
    Orr, D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : E118 - E119
12345